PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.70
Negative D/E while Healthcare median is 0.00. Seth Klarman would scrutinize balance sheet quality and look for restructuring potential.
1.04
Net debt aligned with Healthcare median of 1.14. David Dodd would verify if industry standard leverage is appropriate given business cyclicality.
-7.53
Negative coverage while Healthcare median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
90.83
Current ratio exceeding 1.5x Healthcare median of 1.74. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
No Data
No Data available this quarter, please select a different quarter.